Topiramate in pregnancy and breastfeeding.
Recent information suggests that use of the antiepileptic drug topiramate in pregnancy may raise some concerns, especially if used in polytherapy. Moreover, data on the safety of this antiepileptic drug for the breastfed infant are very limited. However, use of topiramate may be unavoidable in women who wish to become pregnant but who have already experienced severe adverse reactions to antiepileptic medications considered relatively safe in this female condition. Hence, we describe the healthy outcome of a male infant exposed to topiramate through the placenta and maternal milk and who was conceived while the mother was undergoing folic acid supplementation.
Gentile
Salvatore
S
Department of Mental Health ASL Salerno 1, Mental Health Center n. 4, Cava de' Tirreni, Salerno, Italy. salvatore_gentile@alice.it
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001942:Breast Feeding; D019587:Dietary Supplements; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D011247:Pregnancy; D018570:Risk Assessment; D000077236:Topiramate; D014815:Vitamins / Q000008:administration & dosage; D055815:Young Adult
D000927:Anticonvulsants; D014815:Vitamins; D000077236:Topiramate; D005632:Fructose; D005492:Folic Acid